Phase III data show efficacy/safety of iclaprim in patients with complicated skin ...(patients. In a combined efficacy analysi...)

Date:10/27/2008

patients. In a combined efficacy analysis, the clinical cure rate at the test-of-cure visit was 82.2 percent for iclaprim versus 85.3 percent for linezolid in the intent-to-treat population and cure rates were 92.3 percent and 97.8 percent, respectively, in the per protocol population. Data from the studies also show that iclaprim exhibited a high eradication rate for MRSA (76.4 percent), which was comparable to that of linezolid (78.7 percent).

Overall, iclaprim was found to be safe and well-tolerated at a dose of 0.8 mg/kg in the Phase III ASSIST trials. Adverse events were found to be less frequent among patients treated with iclaprim as compared to linezolid. In earlier Phase I trials, iclaprim was shown to have a low propensity for interactions with other drugs.

"These data further support the safety and efficacy of iclaprim as a potential treatment against complicated skin and skin structure infections," said Jrgen Raths MD, President and CEO of Arpida. "Arpida remains encouraged and optimistic about the potential of iclaprim for the treatment of MRSA and related infections, and looks forward to bringing iclaprim to market, providing a new treatment option for physicians."

The ASSIST Trials

The ASSIST trials were randomized, multi-center, double-blind, Phase III studies designed to establish the efficacy and safety of iclaprim in the treatment of patients with cSSSI known or suspected to be caused by Gram-positive pathogens. The trials were of essentially identical design, making a combined analysis of iclaprim possible in a larger population. A 95 percent confidence interval was used to determine statistical significance of study data and the pre-specified non-inferiority margin (-12.5 percent) was met in all populations in both trials.

A total of 991 patients, 18 years old and over with cSSSIs were enrolled in the trials. Patients were treated for 10 to 14 days with either 0.8 mg/kg iclaprim or 600 mg linezol
'/>"/>

Contact: Dr. Jrgen Raths 41-614-179-660 Zeno Group Source:Eurekalert

0 GOOD

Page: 1 2 3
Related biology news :

1. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
2. Improved foam for varicose veins found to be safe in preliminary results from phase II trial
3. Moms obesity during conception phase may set the stage for offsprings obesity risk
4. Liquid crystal phases of tiny DNA molecules point up new scenario for first life on Earth
5. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
6. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
7. CABI helps phase out dangerous pesticide in EU
8. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
9. New test promises quicker, more accurate evaluation for cystic fibrosis patients
10. How eating fruit and vegetables can improve cancer patients response to chemotherapy
11. UCSF Fresno leading-edge study lends hope to emphysema patients